clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Gbinigie II and Lasserson D Clarithromycin-induced akathisia: a class effect of macrolides? 2016 BMJ Case Rep pmid:27927708
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Noda H et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. 2016 J Gastrointestin Liver Dis pmid:27689190
Giorgio F et al. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. 2016 Scand. J. Gastroenterol. pmid:27687850
Donzelli A Helicobacter pylori Eradication? 2016 Gastroenterology pmid:27590693
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Ferro BE et al. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. 2016 Antimicrob. Agents Chemother. pmid:27458221
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
Christl I et al. Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. 2016 Environ. Sci. Technol. pmid:27438991
Luo XF et al. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. 2016 World J. Gastroenterol. pmid:27433095
Sakurai Y et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. 2016 Adv Ther pmid:27432383
Inagaki K et al. Successful Treatment of Peritoneal Dialysis-related Peritonitis due to Mycobacterium iranicum. 2016 Intern. Med. pmid:27432106
Shiratori S et al. Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection. 2016 Intern. Med. pmid:27432094
Hirasawa K et al. Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. 2016 PLoS ONE pmid:27977675
Mougari F et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. 2016 Expert Rev Anti Infect Ther pmid:27690688
Sluch IM et al. Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. 2016 Cornea pmid:27227391
Laird-Fick HS et al. Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. 2016 Postgrad Med J pmid:27222587
Phiphatpatthamaamphan K et al. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. 2016 Asian Pac. J. Cancer Prev. pmid:27221874
Kim SY et al. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. 2016 BMC Infect. Dis. pmid:27188784
Suzuki S et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. 2016 Am. J. Gastroenterol. pmid:27185079
Xu J et al. Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. 2016 Eur J Drug Metab Pharmacokinet pmid:25652786
Berende A et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. 2016 N. Engl. J. Med. pmid:27028911
D'Erme AM et al. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. 2016 Int. J. Dermatol. pmid:27028670
Klesiewicz K et al. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. 2016 J. Antibiot. pmid:27025351
Kawashima K et al. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. 2016 Dig Liver Dis pmid:27012448
Ormeci A et al. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. 2016 Eur Rev Med Pharmacol Sci pmid:27010145
Dubini M et al. Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. 2016 Ann. Allergy Asthma Immunol. pmid:27009438
Miyashita N et al. Macrolide Therapy for Prevention of Exacerbation in Individuals with Diffuse Aspiration Bronchiolitis. 2016 J Am Geriatr Soc pmid:27000351
Belz D et al. Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. 2016 J Eur Acad Dermatol Venereol pmid:25510444
Niv Y Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. 2016 Digestion pmid:26849820
Song Z et al. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. 2016 Dig Liver Dis pmid:26847964
Vannarath S et al. Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. 2016 Asian Pac. J. Cancer Prev. pmid:26838225
Miyamoto S et al. Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. 2016 Tumour Biol. pmid:26825980
Bohnert JA et al. Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. 2016 Antimicrob. Agents Chemother. pmid:26824939
Gaüzère BA and Malvy D [Vingt-cinquième réunion du comité local de la Société de pathologie exotique, 24 novembre 2015]. 2016 Bull Soc Pathol Exot pmid:26818816
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Li X et al. Macrolides use and the risk of sudden cardiac death. 2016 Expert Rev Anti Infect Ther pmid:27086751
Konstantinidis T et al. Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. 2016 Antimicrob. Agents Chemother. pmid:26643338
Ferro BE et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. 2016 Antimicrob. Agents Chemother. pmid:26643335
Boyanova L et al. Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. 2016 Microb. Drug Resist. pmid:26618567
Wu TS et al. Postcesarean section wound infection caused by Mycobacterium massiliense. 2016 J Microbiol Immunol Infect pmid:26350122
Senatore FJ et al. Helicobacter pylori treatment: Still a work in progress. 2016 Postgrad Med pmid:26490697
Shin WG et al. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. 2016 Helicobacter pmid:26470999
Cerqueira RM et al. How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? 2016 Obes Surg pmid:26467690
Boyanova L et al. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. 2016 Infect Dis (Lond) pmid:26465202
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Ghaith D et al. Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. 2016 J Chemother pmid:26358218
Yoon H et al. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. 2016 Gut Liver pmid:26347514
Liou JM et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. 2016 Gut pmid:26338825